- $39.30m
- $127.14m
- $182.60m
- 59
- 86
- 54
- 73
Annual income statement for Zepp Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 6-K | 6-K |
| Standards: | USG | USG | USG | — | — |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Revenue | |||||
| Total Revenue | 932 | 969 | 616 | 353 | 183 |
| Cost of Revenue | |||||
| Gross Profit | 193 | 202 | 119 | 92.4 | 70.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 899 | 954 | 679 | 384 | 240 |
| Operating Profit | 33.4 | 14.6 | -63 | -30.8 | -57.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 38.5 | 16.5 | -55.4 | -34.6 | -57.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 34 | 14.9 | -45.6 | -32.2 | -71.6 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 33.2 | 21.4 | -42.8 | -31 | -75.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 33.2 | 21.4 | -42.8 | -31 | -75.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.398 | 0.323 | -0.169 | -0.127 | -0.267 |